Document is current
Any future updates will be listed below
-
Authors
Xia, Chenglong https://orcid.org/0000-0002-5895-6342
Colognori, David https://orcid.org/0000-0001-6995-7079
Jiang, Xueyang Stephen
Xu, Ke https://orcid.org/0000-0002-2788-194X
Doudna, Jennifer A. https://orcid.org/0000-0001-9161-999X
-
Funding
Funding for this research was provided by:
Howard Hughes Medical Institute (D-0001, D-0001, D-0001)
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (D-0001, X-0001)
- License Information
-
More Information
Article History
Received: 22 June 2024
Accepted: 17 December 2024
First Online: 18 February 2025
Competing interests
: J.A.D. is a cofounder of Azalea Therapeutics, Caribou Biosciences, Editas Medicine, Evercrisp, Scribe Therapeutics, Intellia Therapeutics and Mammoth Biosciences. J.A.D. is a scientific advisory board member at Evercrisp, Caribou Biosciences, Intellia Therapeutics, Scribe Therapeutics, Mammoth Biosciences, The Column Group, Aditum Bio and Inari. J.A.D. is chief science advisor to Sixth Street, a director at Johnson & Johnson, Altos and Tempus and has a research project sponsored by Apple Tree Partners. C.X. and J.A.D. are inventors on patents applied for by the Regents of the University of California related to Csm complex single-molecule imaging. The remaining authors declare no competing interests.
